Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DENND6A (DENN domain-containing protein 6A), also known as FAM116A, is a member of the DENN domain protein family, which serve as guanine nucleotide exchange factors (GEFs) for Rab small GTPases[1][2][3]. DENND6A functions primarily in vesicular trafficking and is required for the proper positioning of lysosomes within the cell. It acts as a GEF for Rabs, notably Rab34 and Rab14, and is recruited by the lysosomal GTPase Arl8b to facilitate lysosome retrograde transport by activating Rab34; this enables the recruitment of the RILP/dynein complex, driving lysosomes toward the cell center, a process crucial for steady-state autophagy[1][2][4]. Loss of DENND6A disrupts lysosomal clustering, impairs autophagic flux, and alters cell-cell adhesion through effects on cadherin-mediated processes[1][2][3]. DENND6A is linked to disease pathways, particularly those involving neurodegeneration when lysosome function or positioning is compromised[1][2]. There are no known drugs, biomarkers, or direct therapeutic efforts currently targeting DENND6A.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DENN domain-containing protein 6A (DENND6A).